New research into retatrutide, a dual activator for GLP-1 and GIP receptors, are revealing promising results in managing obesity and type 2 diabetes. Preclinical evidence suggest a distinct process contributing to https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/